TScan Therapeutics
TCRX
24 hedge funds and large institutions have $30.4M invested in TScan Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 7 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
16% more capital invested
Capital invested by funds: $26.3M → $30.4M (+$4.11M)
0.76% more ownership
Funds ownership: 50.5% → 51.26% (+0.76%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 25 → 24 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.72M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.5M |
| 3 |
NM
Newtyn Management
New York
|
+$680K |
| 4 |
Morgan Stanley
New York
|
+$49.3K |
| 5 |
LPL Financial
San Diego,
California
|
+$43.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.86M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$1.88M |
| 3 |
Barclays
London,
United Kingdom
|
-$445K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$168K |
| 5 |
Renaissance Technologies
New York
|
-$37K |
TCRX Hedge Fund Activity: Q2 2022 in Review
24 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2022, worth a combined $30.4M — up 16% from $26.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TCRX and 6 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 7 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $3.72M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.86M sold.
- 24 institutional investors held TScan Therapeutics (TCRX) as of Q2 2022, down from 25 in Q1 2022.
- Funds reported $30.4M of TScan Therapeutics stock for Q2 2022, up 16% quarter-over-quarter.
- 6 funds opened new TScan Therapeutics positions in Q2 2022 and 7 closed out, a net change of -1 holder.
- The largest TScan Therapeutics buyer in Q2 2022 was Baker Bros. Advisors, an estimated $3.72M added.
- The largest TScan Therapeutics seller in Q2 2022 was RA Capital Management, an estimated $2.86M sold.
Based on aggregated 13F filings for Q2 2022.